The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Separating cetuximab- vs. chemotherapy-related ILD can be problematic

Publications

Nakano K, Taira S, Ono M, Tomomatsu J, Sasaki T, Shimbashi W, Fukushima H, Yonekawa H, Mitani H, Takahashi S

Incidence and risk factors of interstitial lung disease (ILD) of head and neck cancer patients treated with Cetuximab.

Annals of oncology : official journal of the European Society for Medical Oncology 2017 Oct;28 Suppl 9;ix78

Mayfield JD, Mercado CE, Kaye FJ, Mendenhall WM

Cetuximab-associated pulmonary toxicity in concurrent chemoradiation for the treatment of a squamous cell carcinoma of the head and neck.

Head & neck. 2019;41(4):E55-E58

Satoh T, Gemma A, Kudoh S, Sakai F, Yamaguchi K, Watanabe T, Ishiguro M, Inoshiri S, Izawa M, Sugihara K, Sakata Y

Incidence and clinical features of drug-induced lung injury in patients with advanced colorectal cancer receiving cetuximab: results of a prospective multicenter registry.

Japanese journal of clinical oncology. 2014;44(11):1032-9

Achermann Y, Frauenfelder T, Obrist S, Zaugg K, Corti N, Günthard HF

A rare but severe pulmonary side effect of cetuximab in two patients.

BMJ case reports. 2012;2012

Blumenschein GR Jr, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, Herbst RS, Doescher PO, Choy H, Komaki R

Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(17):2312-8

Neal JW, Heist RS, Fidias P, Temel JS, Huberman M, Marcoux JP, Muzikansky A, Lynch TJ, Sequist LV

Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010;5(11):1855-8

Chua W, Peters M, Loneragan R, Clarke S

Cetuximab-associated pulmonary toxicity.

Clinical colorectal cancer. 2009;8(2):118-20

Hoag JB, Azizi A, Doherty TJ, Lu J, Willis RE, Lund ME

Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review.

Journal of experimental & clinical cancer research : CR. 2009;28(1):113